Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Silo Pharma (NASDAQ:SILO) has entered into a non-binding letter of intent with Hoth Therapeutics (NASDAQ:HOTH) to form a 50:50 joint venture targeting the $16 billion global obesity market. The collaboration focuses on developing a novel therapeutic platform based on glial cell line-derived neurotrophic factor (GDNF), exclusively licensed from the U.S. Department of Veterans Affairs and co-developed with Emory University.
The technology, protected under U.S. Patent No. 10,052,362, targets multiple conditions including obesity, non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes. The partnership combines Hoth's regulatory expertise with Silo's translational capabilities to address a significant unmet need, as obesity affects over 40% of U.S. adults, with veterans being particularly impacted.
Silo Pharma (NASDAQ:SILO) ha firmato una lettera di intenti non vincolante con Hoth Therapeutics (NASDAQ:HOTH) per creare una joint venture al 50:50, rivolta al mercato globale dell'obesità da 16 miliardi di dollari. La collaborazione mira a sviluppare una nuova piattaforma terapeutica basata sul fattore neurotrofico derivato dalle cellule gliali (GDNF), con licenza esclusiva dal Dipartimento per gli Affari dei Veterani degli Stati Uniti e co-sviluppata con la Emory University.
La tecnologia, protetta dal brevetto statunitense n. 10.052.362, è indirizzata a diverse patologie tra cui obesità, steatosi epatica non alcolica (NAFLD) e diabete di tipo 2. La partnership unisce l'esperienza regolatoria di Hoth alle capacità traslazionali di Silo per rispondere a un bisogno sanitario significativo, dato che l'obesità colpisce oltre il 40% degli adulti negli Stati Uniti, con una particolare incidenza tra i veterani.
Silo Pharma (NASDAQ:SILO) ha firmado una carta de intenciones no vinculante con Hoth Therapeutics (NASDAQ:HOTH) para formar una empresa conjunta al 50:50 dirigida al mercado global de obesidad de 16 mil millones de dólares. La colaboración se centra en desarrollar una novedosa plataforma terapéutica basada en el factor neurotrófico derivado de células gliales (GDNF), licenciada exclusivamente por el Departamento de Asuntos de Veteranos de EE. UU. y co-desarrollada con la Universidad de Emory.
La tecnología, protegida bajo la patente estadounidense No. 10,052,362, apunta a múltiples condiciones incluyendo obesidad, enfermedad hepática grasa no alcohólica (NAFLD) y diabetes tipo 2. La asociación combina la experiencia regulatoria de Hoth con las capacidades traslacionales de Silo para abordar una necesidad significativa no cubierta, ya que la obesidad afecta a más del 40% de los adultos en EE. UU., siendo los veteranos especialmente afectados.
Silo Pharma (NASDAQ:SILO)는 Hoth Therapeutics (NASDAQ:HOTH)와 50:50 합작 투자 설립을 위한 구속력 없는 의향서를 체결했으며, 이는 160억 달러 규모의 글로벌 비만 시장을 목표로 합니다. 이번 협력은 미국 재향군인부에서 독점 라이선스를 받은 글리아 세포 유래 신경영양인자(GDNF)를 기반으로 한 새로운 치료 플랫폼 개발에 중점을 두며, 에모리 대학교와 공동 개발되었습니다.
미국 특허 번호 10,052,362로 보호되는 이 기술은 비만, 비알코올성 지방간 질환(NAFLD), 제2형 당뇨병 등 다양한 질환을 대상으로 합니다. 이번 파트너십은 Hoth의 규제 전문성과 Silo의 중개 연구 역량을 결합하여 미국 성인의 40% 이상이 비만으로 고통받고, 특히 재향군인에게 큰 영향을 미치는 중요한 미충족 수요를 해결하고자 합니다.
Silo Pharma (NASDAQ:SILO) a conclu une lettre d'intention non contraignante avec Hoth Therapeutics (NASDAQ:HOTH) pour former une coentreprise à parts égales visant le marché mondial de l'obésité de 16 milliards de dollars. Cette collaboration se concentre sur le développement d'une nouvelle plateforme thérapeutique basée sur le facteur neurotrophique dérivé des cellules gliales (GDNF), sous licence exclusive du Département des Anciens Combattants des États-Unis et co-développée avec l'Université Emory.
Cette technologie, protégée par le brevet américain n° 10 052 362, cible plusieurs pathologies, notamment l'obésité, la stéatose hépatique non alcoolique (NAFLD) et le diabète de type 2. Le partenariat associe l'expertise réglementaire de Hoth aux capacités translationnelles de Silo pour répondre à un besoin important non satisfait, l'obésité touchant plus de 40 % des adultes américains, les anciens combattants étant particulièrement concernés.
Silo Pharma (NASDAQ:SILO) hat eine unverbindliche Absichtserklärung mit Hoth Therapeutics (NASDAQ:HOTH) unterzeichnet, um ein 50:50 Joint Venture zu gründen, das den 16 Milliarden Dollar schweren globalen Adipositas-Markt adressiert. Die Zusammenarbeit konzentriert sich auf die Entwicklung einer neuartigen therapeutischen Plattform basierend auf dem glialen zelllinien-abgeleiteten neurotrophen Faktor (GDNF), der exklusiv vom US Department of Veterans Affairs lizenziert und gemeinsam mit der Emory University entwickelt wurde.
Die Technologie, geschützt durch US-Patent Nr. 10.052.362, zielt auf mehrere Erkrankungen ab, darunter Adipositas, nicht-alkoholische Fettlebererkrankung (NAFLD) und Typ-2-Diabetes. Die Partnerschaft vereint Hoths regulatorische Expertise mit Silos translationalen Fähigkeiten, um einen bedeutenden ungedeckten Bedarf zu adressieren, da Adipositas über 40 % der erwachsenen US-Bevölkerung betrifft, wobei Veteranen besonders betroffen sind.
- Exclusive U.S. license from VA for a potential breakthrough obesity treatment
- Equal 50:50 joint venture structure with Hoth Therapeutics
- Technology protected by U.S. Patent targeting $16 billion market
- Addresses multiple high-value indications including obesity, NAFLD, and type 2 diabetes
- Letter of intent is non-binding, indicating deal uncertainty
- Technology still in preclinical stage with no human trial data
- Faces competition in crowded obesity treatment market
- Development and commercialization timeline uncertain
Insights
Silo Pharma's joint venture with Hoth targeting obesity represents early-stage potential in a massive market, but significant development hurdles remain.
Silo Pharma has entered a non-binding letter of intent to form a 50:50 joint venture with Hoth Therapeutics, focusing on an obesity treatment technology exclusively licensed from the VA and co-developed with Emory University. The key therapeutic candidate centers on glial cell line-derived neurotrophic factor (GDNF), a biologic with preclinical evidence of anti-obesity effects.
This strategic move targets the
From an investment perspective, this represents an extremely early-stage opportunity. The press release indicates preclinical status with no mention of IND filing timelines, human trial readiness, or specific development milestones. The non-binding nature of the agreement means there's still uncertainty about whether the joint venture will materialize as described.
While the market opportunity is substantial, investors should recognize that the obesity treatment landscape has become increasingly competitive, with GLP-1 agonists dominating headlines. This novel GDNF approach would need to demonstrate significant differentiation in efficacy, safety, or delivery to gain traction.
The equal governance structure could be beneficial for Silo shareholders, providing both risk sharing and potential upside, though the specific financial commitments required from each party aren't detailed. The VA connection may provide certain development advantages, particularly for indications affecting veteran populations.
Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University
NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University.
The novel therapeutic platform centers on glial cell line-derived neurotrophic factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. The platform is protected under U.S. Patent No. 10,052,362 and targets multiple high-burden conditions, including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and central obesity.
“With obesity at epidemic levels and no curative therapies available, we believe the VA’s biologic GDNF is potentially a game-changer,” said Eric Weisblum, CEO of Silo Pharma. “We believe that our potential JV collaboration with Hoth aligns with our mission to accelerate groundbreaking science into human trials.”
“This VA-originated obesity technology has the potential to disrupt a
Deal Highlights:
| ● | Exclusive U.S. License from the U.S. Department of Veterans Affairs covering all fields of use | |
| ● | 50/50 joint venture structure with equal equity and governance participation | |
| ● | Lead indication: Obesity and NAFLD — conditions with prevalence among both civilian and veteran populations |
Unmet Need:
Obesity affects over
Strategic Alignment:
The partnership leverages:
| ● | The clinical infrastructure and public mission of the VA | |
| ● | Hoth’s regulatory and development expertise | |
| ● | Silo’s translational capabilities and capital efficiency |
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What is the joint venture agreement between Silo Pharma (NASDAQ:SILO) and Hoth Therapeutics?
What is the market potential for SILO's obesity treatment technology?
What technology is SILO using for their obesity treatment?
How will the partnership between SILO and Hoth Therapeutics work?
What stage of development is SILO's obesity treatment currently in?
